Special Reports – Global Edition
COVID Vaccines
Receive email updates from UWN
Global newsletters Africa newsletters Other (other includes related events and webinars) Data will be processed according to our standard terms & conditions.
|
|
Special Reports – Global Edition
COVID Vaccines
Receive email updates from UWN
Global newsletters Africa newsletters Other (other includes related events and webinars) Data will be processed according to our standard terms & conditions.
|
|
In the United States there is unprecedented political pressure on the development of the ‘Operation Warp Speed’ programme, as US President Donald Trump is hoping a vaccine will emerge before the presidential elections on 3 November. But university leaders and researchers warn of risks to safety and trust.
The University of Oxford has resumed its late-stage clinical trial of a COVID-19 vaccine candidate in the United Kingdom that was halted recently due to a volunteer recipient suffering an unexplained illness. But its trial in the United States has not yet been cleared to resume.
Some leading nationalist-leaning nations are eschewing international collaboration on developing a vaccine, but the scientific community thrives on it and our best chance for successful interventions to address COVID-19 lies with effective research translation across borders, as the COVAX programme seeks to demonstrate.
Artificial intelligence is accelerating progress on screening, identifying and researching promising vaccine candidates against COVID-19. But the usefulness of AI tools hinges on the quality of data at a time when the need for speed in developing vaccines can jeopardise that quality, experts say.
The coronavirus pandemic has brought a huge flurry of global scientific activity, involving collaboration on a scale barely matched during the response to HIV/Aids, open access to data, data sharing at an unprecedented pace and rising public appreciation of the role of science.
The German government is pumping up to €750 million (US$885 million) into research by three domestic pharmaceutical firms in an effort to step up the race to develop a vaccine for COVID-19, which the Federal Institute for Vaccines and Biomedicines says could be approved and available by 2021.